Early detection rate changes from a brain‐responsive neurostimulation system predict efficacy of newly added antiseizure drugs

Abstract

Brain‐responsive neurostimulation (RNS System, NeuroPace) is used to treat medically refractory focal epilepsy and also provides long‐term ambulatory neurophysiologic data. We sought to determine whether these data could predict the clinical response to antiseizure drugs (ASDs).